+884.0%
CVNA vs MRNA
+521.0%
+363.0%
-99.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.3% | +0.7% | -5.0% | -4.3% |
| 7D | -4.3% | -8.2% | +3.9% | -3.4% |
| 30D | -2.4% | +125.6% | -127.9% | -18.7% |
| 3M | +4.5% | +197.1% | -192.6% | -17.6% |
| 6M | +10.2% | +148.5% | -138.3% | -10.8% |
| YTD | -16.7% | +363.3% | -380.0% | -39.7% |
| 1Y | -3.8% | +462.0% | -465.7% | -33.4% |
| 3Y | +648.3% | +26.9% | +621.4% | +528.1% |
| 5Y | +6.6% | -69.6% | +76.2% | -4.6% |
| All | +884.0% | +521.0% | +363.0% | +819.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling